Advertisement

Topics

Samsung Bioepis signs R&D agreement with Takeda

08:22 EDT 21 Aug 2017 | pharmaphorum

Samsung Bioepis is to broaden its research into novel pharmaceuticals with a new R&D agreement with Takeda. Samsung Bioepis is a joint venture between South Korea’s Samsung and Biogen, and has already made its name with a series of biosimila...

Original Article: Samsung Bioepis signs R&D agreement with Takeda

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis signs R&D agreement with Takeda"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...